Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma (DLBCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00556127
Recruitment Status : Completed
First Posted : November 9, 2007
Last Update Posted : November 9, 2007
Information provided by:
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

Brief Summary:
The purpose of this trial was to evaluate efficacy and safety of adding Rituximab to dose-dense and High-Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as first line treatment in young patients with DLBCL at Intermediate-High and High risk aaIPI score

Condition or disease Intervention/treatment Phase
Diffuse Large B-Cell Lymphoma POOR PROGNOSIS Drug: Rituximab Drug: Epirubicin Drug: Cyclophosphamide Drug: Vincristine Drug: Prednisone Drug: Granulocyte-colony-stimulating factor Drug: Mitoxantrone Drug: Cytarabine ARA-C Drug: Dexamethasone Drug: Carmustine BCNU Drug: Etoposide Drug: Melphalan Radiation: Radiotherapy Procedure: PBSC reinfusion Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Programma di Terapia Per Pazienti Affetti da Linfoma Diffuso a Grandi Cellule B CD20 Positive
Study Start Date : June 2002
Actual Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Drug: Rituximab
375 mg/m2 on day 1
Drug: Epirubicin
110 mg/m2 on day 3
Drug: Cyclophosphamide
1200 mg/m2 on day 3
Drug: Vincristine
1.4 mg/m2 (maximum 2 mg) on day 3
Drug: Prednisone
40 mg/m2 from day 1 to 5
Drug: Granulocyte-colony-stimulating factor
(G-CSF 5 μg/Kg/day) from day 5 to day 11
Drug: Mitoxantrone
8 mg/m2 for 3-day
Drug: Cytarabine ARA-C
2 g/m2/12 hours for six doses in 3-hour infusion
Drug: Dexamethasone
4 mg/m2/12 hours before ARA-C administration
Drug: Carmustine BCNU
300 mg/m2 on day -7
Drug: Etoposide
100 mg/m2/12 hours
Drug: Melphalan
140 mg/m2 on day -2
Radiation: Radiotherapy
Involved Field Radiotherapy (IF-RT)
Procedure: PBSC reinfusion

Primary Outcome Measures :
  1. Failure-free survival [ Time Frame: Three years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • previously untreated aggressive B-cell lymphoma (Diffuse Large B-Cell,
  • Primary Mediastinal,
  • Follicular grade III b Lymphoma);
  • age 18 to 60;
  • III-IV Ann Arbor stage;
  • 0-2 Eastern Cooperative Oncology Group (ECOG) performance status (PS);
  • intermediate-high (IH) and high (H) risk score according to age-adjusted International Prognostic Index (IPI).
  • Patients with Primary Mediastinal Lymphoma were included only if they had advanced stage III or IV disease.

Exclusion Criteria:

  • HIV,
  • hepatitis B or C virus seropositivity;
  • CNS involvement at diagnosis;
  • abnormal renal, pulmonary and hepatic function;
  • left ventricular ejection fraction less than 45%;
  • pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00556127

Az. Ospedaliera SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
Ospedale Regionale, Divisione di Oncologia,
Aosta, Italy
Azienda Ospedaliera Ospedale Policlinico Consorziale
Bari, Italy
Osp. degli Infermi
Biella, Italy
Spedali Civili
Brescia, Italy
Centro Trapianti Midollo Osseo, P.O. Businco
Cagliari, Italy
Ospedale S. Gerardo
Monza, Italy
Osp. maggiore della Carità
Novara, Italy
Università degli Studi Policlinico Monteluce
Perugia, Italy
Divisione di Medicina, Ospedale Generale E. Agnelli, Pinerolo
Torino, Italy
Istituto per la Ricerca e la Cura del Cancro, Candiolo
Torino, Italy
Osp. S. Giovanni Battista "Molinette"
Torino, Italy
Ospedale di Chivasso e Ivrea
Torino, Italy
Stabilimento Ospedaliero Ciriè -
Torino, Italy
Sponsors and Collaborators
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Principal Investigator: Umberto Vitolo, MD S.C. Ematologia II - OSP.S. GIOV.BATTISTA MOLINETTE - TORINO (TO) - Identifier: NCT00556127     History of Changes
Other Study ID Numbers: GIMURELL-DLBCL
Eudract Number 2004-000543-19
First Posted: November 9, 2007    Key Record Dates
Last Update Posted: November 9, 2007
Last Verified: November 2007

Keywords provided by Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie:
Large B-cell Lymphoma

Additional relevant MeSH terms:
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents